

APRIL 6, 1992

Mr. Chairman. Members of the Committee:

*KATE*  
*35*  
I AM BILL OTTERSON, DIRECTOR OF THE UCSD CONNECT PROGRAM IN TECHNOLOGY AND ENTREPRENEURSHIP; A MEMBER OF THE BOARD OF DIRECTORS OF BIOCOM, THE SAN DIEGO COMMERCIAL SUPPORT GROUP FOR THE BIOTECH INDUSTRY; A MEMBER OF THE BOARD OF DIRECTORS AND A PAST PRESIDENT OF THE UCSD CANCER CENTER FOUNDATION; A DIRECTOR OF THE NATIONAL ASSOCIATION OF CANCER PATIENTS; AND A CANCER PATIENT FOR TWELVE YEARS WITH MULTIPLE MYELOMA.

ALL OF THESE INTERESTS OF MINE HAVE ONE UNIFYING THREAD - MY INTEREST IN PROMOTING CANCER RESEARCH.

*tritium*  
*LOW ENERGY*  
*FOR EXAM*  
*1:30*  
AS THE DIRECTOR OF BIOCOM, I AM IN TOUCH WITH MOST OF THE BIOTECH INDUSTRY IN SAN DIEGO AND KNOW OF THEIR INTERESTS IN A DISPOSAL SITE FOR LOW LEVEL RADIOACTIVE MATERIAL. AS A DIRECTOR OF THE UCSD CANCER RESEARCH FOUNDATION, I AM AWARE OF THE USE OF TRITIUM, CARBON-14, YTRIUM, IODINE AND OTHER LONG-LIVED RADIONUCLIDES IN CANCER RESEARCH, ~~FROM TRITIUM BEING USED FOR MARKING THE PROCESS OF EXPERIMENTAL PHARMACEUTICALS AS THEY ARE METABOLIZED BY THE BODY TO YTRIUM BEING TIPPED ON TO ANTIIDEOTYPIC MONOCLONAL ANTIBODIES AS A POTENTIAL "MAGIC BULLET" FOR TREATMENT OF CERTAIN SOLID TUMORS, LIKE B-CELL LYMPHOMA.~~

BUT TODAY, I AM TESTIFYING AS A DIRECTOR OF THE NATIONAL ASSOCIATION OF CANCER PATIENTS, WHICH I COFOUNDED WITH THE PRESIDENT OF THE PREUSS FOUNDATION FOR BRAIN TUMOR RESEARCH FOR THE PURPOSE OF ENHANCING AND ENCOURAGING STATE-OF-THE-ART CANCER RESEARCH.